{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3"},{"groupId":"OG001","value":"28.6"},{"groupId":"OG002","value":"12.5"},{"groupId":"OG003","value":"22.2"},{"groupId":"OG004","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"description":"Alpha subunit levels were determined at a central laboratory.","groups":[{"description":"Week 12 of Main Phase","id":"OG000","title":"Week 12"},{"description":"Week 24 of Main Phase","id":"OG001","title":"Week 24"},{"description":"Week 48 of Extension Phase","id":"OG002","title":"Week 48"},{"description":"Week 72 of Extension Phase","id":"OG003","title":"Week 72"},{"description":"Week 96 of Extension Phase","id":"OG004","title":"Week 96"}],"paramType":"NUMBER","populationDescription":"Evaluable participants had to have 50% reduction","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately Week 96","title":"Percentage of Participants With Reduction From Baseline of Alpha Subunit ≥50% in Main and Extension Phases (FAS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}